标题
Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
作者
关键词
-
出版物
Frontiers in Immunology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-08-09
DOI
10.3389/fimmu.2021.705096
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Identification of Immune-Related Prognostic Biomarkers Associated with HPV-Positive Head and Neck Squamous Cell Carcinoma
- (2021) Yifei Chen et al. Journal of Immunology Research
- Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma
- (2021) Peng Zhu et al. MEDICINE
- Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
- (2020) Andrea Botticelli et al. Journal of Translational Medicine
- Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
- (2020) Jiahang Mo et al. World Journal of Surgical Oncology
- Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
- (2020) R.L. Ferris et al. ANNALS OF ONCOLOGY
- Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis
- (2020) Ashley Lau et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
- (2020) Alessio Cortellini et al. EUROPEAN JOURNAL OF CANCER
- The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy
- (2020) Andrea Botticelli et al. Vaccines
- The 5-Ws of immunotherapy in head and neck cancer
- (2020) Andrea Botticelli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
- (2020) Paolo Marchetti et al. Journal of Translational Medicine
- The first-week proliferative response of peripheral blood PD-1+CD8+ T cells predicts the response to anti-PD-1 therapy in solid tumors
- (2019) Kyung Hwan Kim et al. CLINICAL CANCER RESEARCH
- A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
- (2019) Andrea Botticelli et al. Journal of Translational Medicine
- Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck
- (2019) Elie El Rassy et al. Future Oncology
- Sex hormones and anticancer immunity
- (2019) Berna C. Özdemir et al. CLINICAL CANCER RESEARCH
- CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy
- (2019) Benedetto Sacchetti et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
- (2019) Joel Guigay et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor‐infiltrating lymphocyte quantification stratifies early‐stage human papillomavirus oropharynx cancer prognosis
- (2019) Farhoud Faraji et al. LARYNGOSCOPE
- Advances in the Management of HPV-Related Oropharyngeal Cancer
- (2019) F. De Felice et al. Journal of Oncology
- The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer
- (2019) Hao Chen et al. CANCER SCIENCE
- Macrophages and Metabolism in the Tumor Microenvironment
- (2019) Ilio Vitale et al. Cell Metabolism
- Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy
- (2019) Mark Lee et al. Human Vaccines & Immunotherapeutics
- Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
- (2019) Mehmet Asim Bilen et al. BMC CANCER
- Assessment of Tumor-infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma
- (2019) Talia L. Fuchs et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Melanoma: prognostic factors and factors predictive of response to therapy
- (2019) Martina Strudel et al. CURRENT MEDICINAL CHEMISTRY
- CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer
- (2019) Bruna Cerbelli et al. VIRCHOWS ARCHIV
- First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
- (2018) Christopher J.D. Wallis et al. EUROPEAN UROLOGY
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- Immunotherapy in head and neck cancer – scientific rationale, current treatment options and future directions
- (2018) SWISS MEDICAL WEEKLY
- The Confluence of Sex Hormones and Aging on Immunity
- (2018) Melanie R. Gubbels Bupp et al. Frontiers in Immunology
- A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
- (2018) S. N. Gettinger et al. Nature Communications
- Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
- (2018) Dan P. Zandberg et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis
- (2018) Yi Ming Weng et al. OncoTargets and Therapy
- Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
- (2018) Lillian L. Siu et al. JAMA Oncology
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
- (2017) Joshua Bauml et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy
- (2017) P. S. Chowdhury et al. JOURNAL OF INTERNAL MEDICINE
- Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis
- (2017) Kentaro Inamura et al. LUNG CANCER
- The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
- (2017) Andrea Botticelli et al. Oncotarget
- Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma
- (2017) Yubo Jiang et al. Oncotarget
- PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
- (2017) Bruna Cerbelli et al. Biomed Research International
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational signatures associated with tobacco smoking in human cancer
- (2016) L. B. Alexandrov et al. SCIENCE
- Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
- (2015) J. Guigay et al. ANNALS OF ONCOLOGY
- Ranking treatments in frequentist network meta-analysis works without resampling methods
- (2015) Gerta Rücker et al. BMC Medical Research Methodology
- Immunology and Immunotherapy of Head and Neck Cancer
- (2015) Robert L. Ferris JOURNAL OF CLINICAL ONCOLOGY
- Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- (2015) Assuntina G. Sacco et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
- (2015) B. Boyerinas et al. Cancer Immunology Research
- Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma
- (2014) Joseph M. Curry et al. SEMINARS IN ONCOLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Network meta-analysis, electrical networks and graph theory
- (2012) Gerta Rücker Research Synthesis Methods
- HPV and head and neck cancer
- (2011) X. Dufour et al. European Annals of Otorhinolaryngology-Head and Neck Diseases
- T Cell-Tumor Interaction Directs the Development of Immunotherapies in Head and Neck Cancer
- (2010) A. E. Albers et al. Clinical & Developmental Immunology
- Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment
- (2009) Shanthi Marur et al. MAYO CLINIC PROCEEDINGS
- Recent Advances in Head and Neck Cancer
- (2008) Robert I. Haddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started